Archives
TCF25 Regulates Lysosomal Acidification and Cell Fate in Glu
2026-05-10
TCF25 Regulates Lysosomal Acidification and Cell Fate in Glucose Starvation
Study Background and Research Question
Glucose availability is central to cellular energy homeostasis and survival. Under conditions of glucose deprivation, cells activate a network of adaptive responses—primarily AMPK activation and autophagy—to maintain ATP levels and limit damage. However, the mechanisms by which cells balance metabolic adaptation with the risk of cell death upon prolonged nutrient stress remain incompletely understood. The lysosome, as the key site for autophagic degradation and metabolic signaling, is increasingly recognized as a hub for integrating these stress responses. Ren et al. (2025) address a critical gap: identifying molecular sensors that govern the lysosomal response to glucose starvation and dictate cell fate decisions (paper).Key Innovation from the Reference Study
The central innovation in Ren et al. is the identification of the transcription factor TCF25 as a nutrient sensor that enhances lysosomal acidification under glucose starvation. TCF25 achieves this by upregulating V-ATPase activity, thereby promoting autophagic flux and ATP maintenance in the early stages of starvation. Strikingly, during prolonged starvation, TCF25-driven lysosomal activity shifts from being protective to pro-death, as it triggers ferritinophagy, lysosomal membrane permeabilization, and ultimately lysosome-dependent cell death (LDCD). This dual role of TCF25 in both adaptation and cell death represents a significant advance in understanding metabolic stress responses (paper).Methods and Experimental Design Insights
Ren et al. employed a genome-wide CRISPR-Cas9 knockout screen to uncover genes essential for cell death in glucose-starved human cell lines. The screen revealed a strong enrichment of lysosomal pathway genes, with a focus on TCF25. Functional validation included knockout and rescue experiments, targeted protein analyses, and measurements of lysosomal pH and autophagic flux, using both in vitro cell models and in vivo mouse models of hepatic ischemia-reperfusion injury (IRI). Knockout of TCF25 or V-ATPase subunits abrogated glucose-starvation-induced cell death, implicating this axis as essential for the observed phenotype (paper).Protocol Parameters
- CRISPR-Cas9 screening | genome-wide library | cell death phenotype under glucose deprivation | unbiased identification of essential regulators | paper
- Lysosomal pH measurement | LysoSensor probe, ratio-metric fluorescence | detection of acidification shifts in wild-type vs. TCF25-deficient cells | establishes TCF25's effect on lysosomal V-ATPase activity | paper
- Ferritinophagy assessment | ferritin degradation rates, LC3-II flux, co-localization imaging | time-course under starvation | links TCF25, autophagy, and iron handling | paper
- Mouse hepatic IRI model | TCF25 knockout vs. wild-type, infarct size quantification | in vivo validation of cellular findings | demonstrates physiological relevance | paper
- Iron chelator use for mechanistic dissection | Deferasirox Fe3+ chelate, 20–50 μM in DMSO | in vitro models of ferritinophagy and lysosomal iron handling | mechanistic specificity for ferric iron sequestration | workflow_recommendation
Core Findings and Why They Matter
The study provides several key discoveries:- TCF25 as a critical regulator of cell fate under glucose deprivation: Loss of TCF25 protects cells from glucose-starvation-induced death, while its presence enhances lysosomal acidification and autophagic flux.
- Lysosomal V-ATPase as a TCF25 effector: TCF25 directly or indirectly upregulates V-ATPase, driving acidification necessary for enhanced autophagy and energy maintenance in early starvation (paper).
- Ferritinophagy and iron metabolism: Under prolonged glucose deprivation, TCF25 promotes ferritinophagy—selective autophagic degradation of ferritin—which increases lysosomal iron and, coupled with membrane permeabilization, leads to LDCD.
- Translational implications: In mouse models, TCF25 deficiency confers protection against hepatic IRI, highlighting a potential therapeutic axis for metabolic and ischemic disorders (paper).
Comparison with Existing Internal Articles
Recent internal articles have explored the role of Deferasirox Fe3+ chelate (Exjade) in mechanistically dissecting iron overload, ferritinophagy, and metabolic adaptation, particularly in beta-thalassemia and chronic anemia models. For example:- The article at Ferritin-Heavy-Chain-Fragment.com details how Deferasirox Fe3+ chelate's robust DMSO solubility and high purity enable precise modeling of iron overload and ferritinophagy. This closely aligns with the tools used by Ren et al. to modulate lysosomal iron content and examine cell death pathways in vitro. The overlap suggests that workflow strategies from beta-thalassemia iron chelation research are relevant for studying lysosomal cell death mechanisms triggered by metabolic stress.
- Similarly, the review at Annexin-V-CY3.com emphasizes actionable protocols for iron chelation in mechanistic cell models, reinforcing the value of Deferasirox Fe3+ chelate for dissecting the specific contributions of ferric iron in autophagic and lysosome-dependent cell death pathways.
Limitations and Transferability
While the study rigorously demonstrates TCF25's role in glucose-starved cell lines and a hepatic IRI mouse model, several limitations should be acknowledged:- Cell type specificity: Most experiments were performed in hepatic and cancer-derived cell lines. Extension to other tissue models (e.g., neuronal, cardiac) remains to be validated (paper).
- Mechanistic boundaries: Although V-ATPase is identified as a key TCF25 effector, the direct transcriptional targets and context-dependent regulation require further elucidation.
- Therapeutic translation: The protective effect of TCF25 deficiency in hepatic IRI models is a promising proof of principle, but therapeutic targeting of this pathway in humans remains speculative at this stage.